Tumorigenicity of IL-1α– and IL-1β–Deficient Fibrosarcoma Cells

Analyzing the growth of fibrosarcoma lines derived from IL-1α-, IL-1β- , or IL-1αβ-knockout (-/-) mice in the immunocompetent host revealed that tumor-derived IL-1α and IL-1β exert strong and opposing effects on immune response induction, which prohibited the evaluation of a potential impact on tumorigenicity. Therefore, in vivo growth of IL-1-deficient tumor lines was evaluated in nu/nu mice and was compared with in vitro growth characteristics. All IL-1-deficient fibrosarcoma lines grow in immunocompromised mice. However, IL-1α-/-β-competent (comp) lines grow more aggressively, efficiently induce angiogenesis, and recruit inflammatory cells. Despite stronger tumorigenicity of IL-1βcomp lines, IL-1α strengthens anchorage-independent growth, but both IL-1α and IL-1β support drug resistance. Corresponding to the aggressive growth, IL-1βcomp cells display increased matrix adhesion, motility, and cable formation on matrigel, likely supported by elevated αv/β3 and matrix metalloroteinase expression. Recruitment of myeloid cells requires IL-1β but is regulated by IL-1α, because inflammatory chemokine and cytokine expression is stronger in IL-1α-/-βcomp than in IL-1wt lines. This regulatory effect of tumor-derived IL-1α is restricted to the tumor environment and does not affect systemic inflammatory response induction by tumor-derived IL-1β. Both sarcoma cell-derived IL-1α and IL-1β promote tumor growth. However, IL-1α exerts regulatory activity on the tumor cell-matrix cross-talk, and only IL-1β initiates systemic inflammation.

[1]  M. Zöller,et al.  Opposing effects of fibrosarcoma cell‐derived IL‐1α and IL‐1β on immune response induction , 2008, International journal of cancer.

[2]  Lewis C. Cantley,et al.  AKT/PKB Signaling: Navigating Downstream , 2007, Cell.

[3]  D. Brough,et al.  Mechanisms of regulation for interleukin-1β in neurodegenerative disease , 2007, Neuropharmacology.

[4]  A. Osterman,et al.  Bcl-2 and Bcl-XL Regulate Proinflammatory Caspase-1 Activation by Interaction with NALP1 , 2007, Cell.

[5]  F. Martinez,et al.  Therapeutic targeting of CC ligand 21 or CC chemokine receptor 7 abrogates pulmonary fibrosis induced by the adoptive transfer of human pulmonary fibroblasts to immunodeficient mice. , 2007, The American journal of pathology.

[6]  Tracy M Handel,et al.  Chemokine: receptor structure, interactions, and antagonism. , 2007, Annual review of immunology.

[7]  Yoichiro Iwakura,et al.  Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. , 2007, Cancer research.

[8]  R. Kaplan,et al.  Niche-to-niche migration of bone-marrow-derived cells. , 2007, Trends in molecular medicine.

[9]  S. Girardin,et al.  Chronic inflammation: importance of NOD2 and NALP3 in interleukin‐1β generation , 2006 .

[10]  A. Paoletti,et al.  Evidence implicating matrix metalloproteinases in the mechanism underlying accumulation of IL-1beta and neuronal apoptosis in the neocortex of HIV/gp120-exposed rats. , 2007, International review of neurobiology.

[11]  M. Neuenhahn,et al.  NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. , 2007, Cell.

[12]  S. Frede,et al.  Regulation of hypoxia-inducible factors during inflammation. , 2007, Methods in enzymology.

[13]  Charis Eng,et al.  Cancer phenomics: RET and PTEN as illustrative models , 2007, Nature Reviews Cancer.

[14]  S. Mariathasan,et al.  Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation , 2007, Nature Reviews Immunology.

[15]  É. Hajduch,et al.  IL‐1 receptor antagonist in metabolic diseases: Dr Jekyll or Mr Hyde? , 2006, FEBS letters.

[16]  Claudia Rubie,et al.  Chemokine receptor CCR6 expression in colorectal liver metastasis. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  H. Alexander,et al.  Journal of Translational Medicine Interleukin-1 and Cancer Progression: the Emerging Role of Interleukin-1 Receptor Antagonist as a Novel Therapeutic Agent in Cancer Treatment , 2022 .

[18]  S. Paterson-Brown,et al.  Elevated tumour interleukin-1β is associated with systemic inflammation: a marker of reduced survival in gastro-oesophageal cancer , 2006, British Journal of Cancer.

[19]  Y. Carmi,et al.  The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions , 2006, Cancer and Metastasis Reviews.

[20]  C. Dinarello,et al.  The paradox of pro-inflammatory cytokines in cancer , 2006, Cancer and Metastasis Reviews.

[21]  D. Gabrilovich,et al.  Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer , 2006, Cancer and Metastasis Reviews.

[22]  A. Zalatnai.  Molecular aspects of stromal-parenchymal interactions in malignant neoplasms. , 2006, Current molecular medicine.

[23]  S. Argov,et al.  Immune phenomena involved in the in vivo regression of fibrosarcoma cells expressing cell‐associated IL‐1α , 2006, Journal of leukocyte biology.

[24]  P. Sharp,et al.  A positive feedback loop couples Ras activation and CD44 alternative splicing. , 2006, Genes & development.

[25]  Y. Iwakura,et al.  IL-1β Breaks Tolerance through Expansion of CD25+ Effector T Cells1 , 2006, The Journal of Immunology.

[26]  H. Cui,et al.  Evidence that hypoxia-inducible factor-1 (HIF-1) mediates transcriptional activation of interleukin-1β (IL-1β) in astrocyte cultures , 2006, Journal of Neuroimmunology.

[27]  C. Akdis,et al.  Mechanisms of immune suppression by interleukin‐10 and transforming growth factor‐β: the role of T regulatory cells , 2006, Immunology.

[28]  Y. Carmi,et al.  Effects of micro-environment- and malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour-host interactions. , 2006, European journal of cancer.

[29]  Federico Bussolino,et al.  Integrins and angiogenesis: a sticky business. , 2006, Experimental cell research.

[30]  S. Brand,et al.  Cell differentiation dependent expressed CCR6 mediates ERK‐1/2, SAPK/JNK, and Akt signaling resulting in proliferation and migration of colorectal cancer cells , 2006, Journal of cellular biochemistry.

[31]  Paolo Serafini,et al.  Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. , 2006, Seminars in cancer biology.

[32]  J. Leips,et al.  Inflammation Induces Myeloid-Derived Suppressor Cells that Facilitate Tumor Progression1 , 2006, The Journal of Immunology.

[33]  Y. Iwakura,et al.  IL-1 beta breaks tolerance through expansion of CD25+ effector T cells. , 2006, Journal of immunology.

[34]  H. Wajant.  CD95L/FasL and TRAIL in tumour surveillance and cancer therapy. , 2006, Cancer treatment and research.

[35]  M. Tomonaga,et al.  Chemokine expression in human erythroid leukemia cell line AS-E2: macrophage inflammatory protein-3alpha/CCL20 is induced by inflammatory cytokines. , 2006, Experimental hematology.

[36]  R. Ferris,et al.  CCR7 mediates inflammation-associated tumor progression , 2006, Immunologic research.

[37]  D. Roy,et al.  Levels of IL-1 beta control stimulatory/inhibitory growth of cancer cells. , 2006, Frontiers in bioscience : a journal and virtual library.

[38]  S. Segal,et al.  CD11b+/Gr-1+ Immature Myeloid Cells Mediate Suppression of T Cells in Mice Bearing Tumors of IL-1β-Secreting Cells1 , 2005, The Journal of Immunology.

[39]  R. Strieter,et al.  Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1 beta-induced neovascularization and tumor growth. , 2005, The Journal of clinical investigation.

[40]  M. Zöller,et al.  CD44v6 promotes proliferation by persisting activation of MAP kinases. , 2005, Cellular signalling.

[41]  M. Dobrovolskaia,et al.  Inflammation and cancer: when NF-kappaB amalgamates the perilous partnership. , 2005, Current cancer drug targets.

[42]  S. Kunkel,et al.  Neutrophil-derived cytokines: potential therapeutic targets in inflammation. , 2005, Current drug targets. Inflammation and allergy.

[43]  C. Dinarello.  Blocking IL-1 in systemic inflammation , 2005, The Journal of experimental medicine.

[44]  V. A. Flørenes,et al.  Phorbol ester phorbol-12-myristate-13-acetate promotes anchorage-independent growth and survival of melanomas through MEK-independent activation of ERK1/2. , 2005, Biochemical and biophysical research communications.

[45]  Kebin Liu,et al.  Cooperative disengagement of Fas and intercellular adhesion molecule-1 function in neoplastic cells confers enhanced colonization efficiency. , 2005, Cancer research.

[46]  T. Okada,et al.  A novelin vitro assay system for transendothelial tumor cell invasion: significance of E-selectin and α3 integrin in the transendothelial invasion by HT1080 fibrosarcoma cells , 1994, Clinical & Experimental Metastasis.

[47]  Lu‐Hai Wang.  Molecular signaling regulating anchorage-independent growth of cancer cells. , 2004, The Mount Sinai journal of medicine, New York.

[48]  P. Vandenabeele,et al.  Caspase-1 Activates Nuclear Factor of the κ-Enhancer in B Cells Independently of Its Enzymatic Activity* , 2004, Journal of Biological Chemistry.

[49]  F. Martinon,et al.  Inflammatory Caspases Linking an Intracellular Innate Immune System to Autoinflammatory Diseases , 2004, Cell.

[50]  C. Dinarello,et al.  The precursor form of IL-1alpha is an intracrine proinflammatory activator of transcription. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[51]  P. Swaan,et al.  Sequential Processing of Human ProIL-1β by Caspase-1 and Subsequent Folding Determined by a Combined In Vitro and In Silico Approach , 2001, Pharmaceutical Research.

[52]  S. Segal,et al.  Differential Effects of IL-1α and IL-1β on Tumorigenicity Patterns and Invasiveness 1 , 2003, The Journal of Immunology.

[53]  J. Van Damme,et al.  The CC chemokine CCL20 and its receptor CCR6. , 2003, Cytokine & growth factor reviews.

[54]  V. Bronte,et al.  L-arginine metabolism in myeloid cells controls T-lymphocyte functions. , 2003, Trends in immunology.

[55]  Y. Iwakura,et al.  IL-1 is required for tumor invasiveness and angiogenesis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[56]  O. Söder,et al.  Expression and regulation of the prointerleukin-1alpha processing enzymes calpain I and II in the rat testis. , 2003, International journal of andrology.

[57]  E. Voronov,et al.  Interleukin-1--a major pleiotropic cytokine in tumor-host interactions. , 2002, Seminars in cancer biology.

[58]  W. Arend.  The balance between IL-1 and IL-1Ra in disease. , 2002, Cytokine & growth factor reviews.

[59]  Kazuhiro Usui,et al.  Proinflammatory Cytokine IL-1β Promotes Tumor Growth of Lewis Lung Carcinoma by Induction of Angiogenic Factors: In Vivo Analysis of Tumor-Stromal Interaction1 , 2002, The Journal of Immunology.

[60]  D. MacEwan.  TNF receptor subtype signalling: differences and cellular consequences. , 2002, Cellular signalling.

[61]  B. Aggarwal,et al.  Tumour necrosis factors receptor associated signalling molecules and their role in activation of apoptosis, JNK and NF-κB , 2000, Annals of the rheumatic diseases.

[62]  M. Zöller,et al.  Antitumor and immunotherapeutic effects of activated invasive T lymphoma cells that display short-term interleukin 1alpha expression. , 1999, Cancer research.

[63]  Masatoshi Suzuki,et al.  Production of Mice Deficient in Genes for Interleukin (IL)-1α, IL-1β, IL-1α/β, and IL-1 Receptor Antagonist Shows that IL-1β Is Crucial in Turpentine-induced Fever Development and Glucocorticoid Secretion , 1998, The Journal of experimental medicine.

[64]  M. Young,et al.  Myeloid differentiation treatment to diminish the presence of immune-suppressive CD34+ cells within human head and neck squamous cell carcinomas. , 1997, Journal of immunology.

[65]  C. Dinarello,et al.  Biologic basis for interleukin-1 in disease. , 1996, Blood.

[66]  G. Klein,et al.  Methylcholanthrene-induced mouse sarcomas express individually distinct major histocompatibility complex class I-associated peptides recognized by specific CD8+ T-cell lines. , 1995, Cancer research.

[67]  P. Leder,et al.  The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation , 1995, The Journal of experimental medicine.

[68]  P. Leder,et al.  IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo , 1993, The Journal of experimental medicine.

[69]  M. Zöller,et al.  Reduced tumorigenicity of fibrosarcomas which constitutively generate il‐1α either spontaneously or following il‐1α gene transfer , 1992 .

[70]  L. Burkly,et al.  Cloning of murine and rat vascular cell adhesion molecule-1. , 1992, Biochemical and biophysical research communications.

[71]  M. Zöller,et al.  Interleukin‐1 production by transformed fibroblasts. II. Influence on antigen presentation and T‐cell‐mediated anti‐tumor response , 1992, International journal of cancer.

[72]  M. Zöller,et al.  Reduced tumorigenicity of fibrosarcomas which constitutively generate IL-1 alpha either spontaneously or following IL-1 alpha gene transfer. , 1992, International journal of cancer.

[73]  M. Young,et al.  Differential Induction of Hematopoiesis and Immune Suppressor Cells in the Bone Marrow Versus in the Spleen by Lewis Lung Carcinoma Variants , 1989, Journal of leukocyte biology.